ncorporated in 2010, Stemergie is a spin-off company from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE). Stemergie develops treatments and diagnostics for cancers by targeting cancer-initiating cells (CIC), the roots of cancer. Stemergie has identified and validated molecules that specifically eradicate brain CICs while having a low effect on cancer cells or normal brain cells. Stemergie’s effective treatments targeting the roots of cancer in combination with the current standard treatments have a high potential to increase the survival rate of the brain tumor patient. Stemergie’s CIC based technology allows the identification, validation and development of treatments against brain CICs. With its proprietary methodology, Stemergie is able to identify, isolate and enrich CICs independently of any marker. Stemergie will apply this technology to other types of CICs to treat and diagnose colon cancers and other oncological diseases.